NMN vs Nicotinamide Riboside

Both raise NAD+ levels. Nicotinamide riboside is converted to NMN by the enzyme NRK, and NMN is then converted to NAD+. Human trials of both show NAD+ increases, with modest functional results.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

NMN

A direct precursor of NAD+, studied in human trials as a way to raise NAD+ levels that decline with age.

BEST STUDIED FOR

Mitochondrial & longevity

Read the cited profile →

🧪

	NMN	Nicotinamide Riboside
The key difference	NAD+ precursor (one step closer)	NAD+ precursor (converted to NMN)
Class	Mitochondrial & longevity	Mitochondrial & longevity
Mechanism	NMN is converted to NAD+ by NMNAT enzymes; NAD+ is a cofactor for energy metabolism and for sirtuins and PARPs.	NR is phosphorylated by NRK enzymes to NMN and then to NAD+.
Status	Multiple small randomised human trials (insulin sensitivity, walking speed, aerobic capacity, sleep). Regulatory status of NMN as a supplement varies by country.	Multiple randomised trials (safety, Parkinson’s, MCI, COPD, PAD); GRAS status for food use in the US.
Reported safety signals	Trials and reviews report it as well tolerated over weeks to months; long-term human data are still limited.	Long-term trials in overweight adults and a high-dose Parkinson’s safety trial reported it as well tolerated.
A key study	A randomised trial in prediabetic women measured muscle insulin sensitivity after NMN supplementation. (Science 2021, PMID 33888596)	A phase 1 trial tested whether NR is safe and raises cerebral NAD in Parkinson’s disease. (Cell Metab 2022, PMID 35235774)

They answer the same question by different entry points; NR has more published human trials. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[NMN] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women — Science 2021. PMID 33888596
[NMN] The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial — Geroscience 2023. PMID 36482258
[NMN] Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study — Geroscience 2024. PMID 38789831
[Nicotinamide Riboside] The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease — Cell Metab 2022. PMID 35235774
[Nicotinamide Riboside] NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease — Nat Commun 2023. PMID 38016950
[Nicotinamide Riboside] Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults — Sci Rep 2019. PMID 31278280

FREQUENTLY ASKED

What is the difference between NMN and Nicotinamide Riboside?

Both raise NAD+ levels. Nicotinamide riboside is converted to NMN by the enzyme NRK, and NMN is then converted to NAD+. Human trials of both show NAD+ increases, with modest functional results.

What is the regulatory status of NMN and Nicotinamide Riboside?

NMN: Multiple small randomised human trials (insulin sensitivity, walking speed, aerobic capacity, sleep). Regulatory status of NMN as a supplement varies by country. Nicotinamide Riboside: Multiple randomised trials (safety, Parkinson’s, MCI, COPD, PAD); GRAS status for food use in the US.

What safety signals have been reported?

NMN: Trials and reviews report it as well tolerated over weeks to months; long-term human data are still limited. Nicotinamide Riboside: Long-term trials in overweight adults and a high-dose Parkinson’s safety trial reported it as well tolerated.

Which studies is this comparison based on?

For NMN: “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women” (PMID 33888596); “The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial” (PMID 36482258); “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study” (PMID 38789831). For Nicotinamide Riboside: “The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease” (PMID 35235774); “NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease” (PMID 38016950); “Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults” (PMID 31278280).